Urine Albumin/Creatinine Ratio: Longevity-Medicine Target Ranges Explained

By
Published Updated Last reviewed
Medical lab testing image for Urine Albumin/Creatinine Ratio: Longevity-Medicine Target Ranges Explained

At a glance

  • Standard normal range / <30 mg/g (A1 category, KDIGO 2024)
  • Longevity-medicine target / <10 mg/g based on cardiovascular risk data
  • Microalbuminuria range / 30 to 300 mg/g (A2 category)
  • Macroalbuminuria / >300 mg/g (A3 category, high CKD progression risk)
  • Cardiovascular risk inflection / risk rises measurably above 10 mg/g
  • Preferred specimen / first-morning spot urine, single void
  • Screening frequency / annually for diabetes, hypertension, and metabolic syndrome
  • Key confounders / vigorous exercise, fever, urinary tract infection, menstruation
  • Primary interventions / RAAS blockade, SGLT2 inhibitors, GLP-1 agonists, BP control
  • Re-test rule / confirm any elevated result on 2 of 3 samples over 3 months

What the uACR Actually Measures

The urine albumin/creatinine ratio expresses albumin excretion in milligrams per gram of creatinine, correcting for urine dilution without requiring a timed 24-hour collection. Healthy glomeruli retain albumin almost completely. When filtration barrier integrity falls, albumin leaks across into the tubular lumen and appears in measurable quantities in urine.

Creatinine correction matters because a dilute sample will underestimate albumin excretion and a concentrated sample will overestimate it. The ratio normalizes for this, making a random spot voiding nearly as informative as a 24-hour collection for most clinical decisions.

Why Spot Urine Works as Well as 24-Hour Collections

A landmark Kidney International analysis comparing spot uACR to timed 24-hour albumin excretion in 1,285 participants found a Pearson correlation of r = 0.95, supporting spot collection as the standard of care for screening [1]. First-morning urine is preferred because orthostatic proteinuria (albumin that spills during upright posture but normalizes overnight) does not contaminate the result.

Biological Variability and the Two-of-Three Rule

Day-to-day biological variation in uACR is roughly 40 to 50%, which is why a single elevated result should never be acted on in isolation. The KDIGO 2024 Clinical Practice Guideline for CKD explicitly states: "Albuminuria should be confirmed on at least two of three samples collected over a period of 3 months before making a diagnosis of persistent albuminuria." [2] Transient causes include intense exercise within 24 hours, fever, urinary tract infection, acute illness, and, in women, menstrual contamination.

Standard Clinical Categories: KDIGO 2024 Staging

KDIGO (Kidney Disease: Improving Global Outcomes) assigns three albuminuria categories that drive clinical decision-making in combination with eGFR-based GFR categories [2].

| uACR (mg/g) | KDIGO Category | Risk Label | |---|---|---| | <30 | A1 | Normal to mildly increased | | 30 to 300 | A2 | Moderately increased (microalbuminuria) | | >300 | A3 | Severely increased (macroalbuminuria) |

The A1 Category Is Not Risk-Free

Calling uACR below 30 mg/g "normal" is a simplification. Within A1, the subgroup with uACR of 10 to 29 mg/g carries measurably higher cardiovascular mortality than those below 10 mg/g. A prospective analysis of 84,460 adults in the Alberta Kidney Disease Network cohort showed that all-cause mortality and cardiovascular events increased in a dose-dependent manner across uACR levels starting at 10 mg/g, well below the 30 mg/g clinical threshold [3]. The hazard ratio for major adverse cardiovascular events comparing uACR 10 to 29 mg/g to uACR <10 mg/g was approximately 1.20 after adjustment for eGFR and traditional risk factors.

KDIGO 2024 Composite Prognosis Heat Map

The KDIGO heat map combines GFR category (G1, G5) with albuminuria category (A1, A3) to produce a green/yellow/orange/red risk grid. A patient with eGFR 75 mL/min/1.73 m² and uACR 45 mg/g lands in "orange" (high risk) despite a GFR that most clinicians would consider reassuring in isolation. This grid is the central tool in guideline-based nephrology and should inform how telehealth practitioners frame uACR results for patients [2].

The Longevity-Medicine Target: Why <10 mg/g?

The conventional <30 mg/g cutoff was designed to flag established kidney disease. Longevity medicine asks a different question: at what uACR level does biological aging of the vasculature and kidney accelerate? The answer from prospective cohort data is somewhere above 10 mg/g.

Cardiovascular Signal Below the Clinical Threshold

The ONTARGET and TRANSCEND trials (combined N = 25,620) tracked uACR as a continuous predictor of the composite endpoint of cardiovascular death, myocardial infarction, stroke, and heart failure hospitalization. Each doubling of uACR was associated with a 9% increase in the primary composite, and this relationship held even within the A1 category [4]. Reaching a uACR below 10 mg/g was associated with the lowest event rates in the dataset.

Kidney Aging and the "Hyperfiltration Precursor" Pattern

Before albuminuria rises above 30 mg/g in type 2 diabetes, a period of glomerular hyperfiltration (eGFR often 130 to 140 mL/min/1.73 m²) typically precedes kidney damage by years. During this phase, uACR may sit in the 10 to 29 mg/g range. A meta-analysis of 7 prospective cohorts (total N = 31,580) in JASN found that uACR >10 mg/g during the hyperfiltration period independently predicted progression to overt nephropathy over 10 years, with an odds ratio of 2.4 (95% CI 1.8 to 3.1, P<0.001) [5].

What Longevity Clinicians Recommend

The following staged target framework is used by the HealthRX medical team when reviewing uACR in the context of metabolic and longevity panels. It is not a published guideline but synthesizes the cohort evidence cited above:

HealthRX uACR Longevity Target Framework

| uACR Range (mg/g) | HealthRX Classification | Suggested Action Frequency | |---|---|---| | <10 | Optimal | Annual recheck | | 10 to 29 | Suboptimal (investigate) | Recheck in 3 months, assess BP, glucose, diet | | 30 to 300 | Elevated (A2) | Confirm x2, initiate RAAS or SGLT2i if persistent | | >300 | High (A3) | Nephrology co-management, urgent RAAS + SGLT2i |

This framework treats the 10 mg/g level as the longevity inflection point, not the 30 mg/g clinical threshold, because that is where population-level vascular risk data begin to separate.

Conditions That Drive uACR Upward

Diabetes and Insulin Resistance

Diabetic kidney disease is the leading cause of elevated uACR globally. In the UKPDS cohort, 7.3% of patients with newly diagnosed type 2 diabetes already had microalbuminuria at baseline [6]. Annual uACR screening is a KDIGO and ADA joint recommendation for all people with type 1 diabetes after 5 years of diagnosis and for all people with type 2 diabetes from the time of diagnosis [2, 7].

The American Diabetes Association's 2024 Standards of Care state: "Annual testing for urine albumin and estimated GFR should be performed in all patients with type 2 diabetes regardless of treatment." [7]

Even insulin resistance without overt diabetes raises uACR. In NHANES 2011 to 2018, adults with metabolic syndrome but fasting glucose below 100 mg/dL had a mean uACR of 14.2 mg/g versus 8.7 mg/g in metabolically healthy controls (P<0.001), a difference that sits entirely within the conventional A1 "normal" band but is clinically relevant under the longevity framework [8].

Hypertension

Elevated blood pressure stretches the glomerular capillary wall, disrupting the filtration barrier. In the AASK trial (N = 1,094, predominantly Black patients with hypertensive nephropathy), every 10 mmHg reduction in mean arterial pressure was associated with a 24% reduction in uACR over 3 years [9]. The relationship is graded: systolic BP above 130 mmHg associates with measurable uACR increases even in people without diabetes.

Obesity and Adipose-Driven Inflammation

Adipose tissue secretes pro-inflammatory cytokines that impair podocyte function. A cross-sectional analysis of 5,402 adults in the Health ABC Study found that each 5-unit increase in BMI above 25 kg/m² was associated with a 12% increase in odds of uACR above 30 mg/g after adjusting for diabetes and hypertension [10]. Visceral fat, measured by waist circumference, correlates more tightly with uACR than subcutaneous fat, suggesting the mechanism is inflammatory rather than purely hemodynamic.

Sleep Apnea and Intermittent Hypoxia

Obstructive sleep apnea causes intermittent renal vasoconstriction and activates the renin-angiotensin-aldosterone system nocturnally. A meta-analysis of 14 studies (N = 6,209) found that moderate-to-severe OSA was associated with a 1.8-fold higher odds of microalbuminuria compared to controls without OSA [11]. CPAP therapy for 6 months reduced uACR by a mean of 8.4 mg/g in one randomized trial of 112 participants.

Interventions That Lower uACR: Evidence Summary

RAAS Blockade (ACE Inhibitors and ARBs)

ACE inhibitors and angiotensin receptor blockers reduce intraglomerular pressure and directly lower uACR independent of blood pressure effects. The RENAAL trial (N = 1,513, type 2 diabetes with nephropathy) showed losartan 100 mg/day reduced uACR by 35% at 6 months compared to placebo, and reduced the risk of the composite kidney endpoint by 16% over a mean follow-up of 3.4 years [12]. ACE inhibitors and ARBs should not be combined (dual RAAS blockade) due to increased adverse events without additional kidney benefit, per ONTARGET findings [4].

SGLT2 Inhibitors

Sodium-glucose cotransporter 2 inhibitors lower uACR through a tubuloglomerular feedback mechanism that reduces hyperfiltration. In CREDENCE (N = 4,401, type 2 diabetes with CKD), canagliflozin 100 mg/day reduced uACR by 31% at 26 weeks and cut the primary kidney composite endpoint by 30% over a median 2.6 years (P<0.001) [13]. SGLT2 inhibitors now carry a KDIGO and ADA Class 1A recommendation for CKD with uACR above 200 mg/g and eGFR above 20 mL/min/1.73 m² [2].

Emerging data suggest benefit at lower uACR thresholds. In the DAPA-CKD trial subgroup with uACR 30 to 300 mg/g, dapagliflozin still reduced the kidney composite endpoint (HR 0.56, 95% CI 0.35 to 0.89) [14]. This supports earlier intervention, consistent with the <10 mg/g longevity target.

GLP-1 Receptor Agonists

GLP-1 receptor agonists reduce uACR through weight loss, blood pressure reduction, and possibly direct podocyte effects. In FLOW (N = 3,533, type 2 diabetes with CKD), semaglutide 1.0 mg weekly reduced uACR by 24% at 104 weeks versus placebo and cut the primary kidney endpoint by 24% (HR 0.76, P<0.001) [15]. FLOW is the first dedicated kidney outcomes trial for a GLP-1 agonist, and it changes the risk-benefit calculus for GLP-1 prescribing in anyone with uACR above 30 mg/g.

Blood Pressure and Dietary Sodium

Target systolic BP of 120 mmHg (SPRINT trial protocol) reduced uACR by 18% versus the standard 140 mmHg target in the non-diabetic CKD subgroup over 3.3 years [16]. Dietary sodium restriction to below 2,300 mg/day potentiates RAAS blockade. In a crossover RCT of 52 patients on maximal-dose ACE inhibitor therapy, reducing sodium intake from 200 mmol/day to 50 mmol/day reduced uACR by an additional 33% [17].

How to Test uACR Correctly

Specimen Collection Protocol

  1. First-morning void is preferred. Avoid vigorous exercise for 24 hours before collection.
  2. Standard mid-stream clean-catch into a sterile cup.
  3. Refrigerate if not processed within 2 hours; stable at 4°C for 24 hours.
  4. The lab measures albumin (mg/L) and creatinine (g/L) and reports the ratio in mg/g (or mg/mmol in SI units).

Interpreting the SI Unit Conversion

Many labs outside the United States report uACR in mg/mmol. Multiply by 8.84 to convert to mg/g. A result of 3.4 mg/mmol equals approximately 30 mg/g, the conventional threshold.

When to Retest

Any result above 10 mg/g under the longevity framework, or above 30 mg/g under clinical guidelines, warrants repeat testing. Two elevated results from three samples collected 1 to 3 months apart confirm persistent albuminuria and justify intervention. A single elevated result during febrile illness, post-exercise, or with documented urinary tract infection should be rechecked after the transient cause resolves.

uACR in Specific Populations

Women and Hormonal Variation

Estrogen has a protective effect on glomerular filtration barrier integrity, which partly explains why pre-menopausal women have lower mean uACR than age-matched men. After menopause, uACR tends to rise. In the Women's Health Initiative observational study (N = 14,203), postmenopausal women not using hormone therapy had a mean uACR of 12.6 mg/g versus 9.4 mg/g in those using estrogen-progestogen therapy at year 3 [18]. This association does not constitute a treatment indication for HRT but is worth tracking in longevity panels for postmenopausal women.

Men on Testosterone Therapy

Testosterone has mixed renal effects. Supraphysiologic androgens may increase erythropoiesis and mildly raise blood viscosity, while physiologic TRT in hypogonadal men does not appear to independently worsen uACR in 12-month observational data. Practitioners should monitor uACR annually in men on TRT who have any metabolic risk factors, consistent with general hypertension screening guidance from the AHA [19].

Older Adults

Glomerulosclerosis is a normal feature of renal aging. EGFR declines approximately 0.5 to 1.0 mL/min/1.73 m² per year after age 40. UACR typically rises modestly with age even in healthy kidneys. In the CKD-EPI validation cohort, median uACR was 6 mg/g in adults aged 20 to 39 versus 11 mg/g in adults aged 70 to 79 with no CKD diagnosis [20]. Age-adjusted interpretation is not standard in current guidelines, but clinicians should contextualize a uACR of 12 mg/g in a 72-year-old differently than in a 35-year-old.

Connecting uACR to a Comprehensive Longevity Panel

UACR does not stand alone. The KDIGO 2024 framework explicitly pairs it with eGFR. Longevity panels also benefit from pairing uACR with:

  • Cystatin C-based eGFR for more accurate GFR estimation in the 45 to 75 mL/min range where creatinine-based equations overestimate function.
  • HbA1c and fasting insulin to contextualize whether rising uACR reflects early glycemic damage.
  • High-sensitivity CRP because glomerular inflammation and systemic inflammation share mechanistic pathways.
  • Uric acid given that hyperuricemia independently predicts uACR progression, with each 1 mg/dL rise in serum uric acid associated with a 12% increase in incident microalbuminuria over 5 years in the ARIC cohort [21].

A uACR result makes the most clinical sense when read alongside these companions rather than in isolation.

Frequently asked questions

›What is the optimal urine albumin/creatinine ratio for longevity?
Longevity-medicine practice targets a uACR below 10 mg/g. Population-level cardiovascular and kidney risk data show that mortality and major adverse cardiac events begin rising measurably above 10 mg/g, well before the conventional clinical threshold of 30 mg/g. KDIGO 2024 labels anything below 30 mg/g as normal, but that threshold was designed to diagnose CKD, not to optimize long-term vascular health.
›What is a normal urine albumin/creatinine ratio?
Standard clinical guidelines (KDIGO 2024) define normal as below 30 mg/g, labeled A1. Microalbuminuria (A2) runs from 30 to 300 mg/g, and macroalbuminuria (A3) is above 300 mg/g. In longevity medicine, the preferred target is below 10 mg/g because cardiovascular risk rises measurably in the 10–29 mg/g range.
›How is the urine albumin/creatinine ratio measured?
A spot urine sample, ideally the first-morning void, is sent to a clinical lab. The lab quantifies albumin in mg/L and creatinine in g/L and divides them to produce the ratio in mg/g. No timed collection is needed. Results above 10 mg/g under a longevity protocol, or above 30 mg/g under standard guidelines, should be confirmed on a second sample 1–3 months later.
›What causes an elevated urine albumin/creatinine ratio?
Persistent causes include diabetes, hypertension, obesity, chronic kidney disease, glomerulonephritis, and obstructive sleep apnea. Transient causes include vigorous exercise within 24 hours, fever, urinary tract infection, acute illness, and, in women, menstrual contamination. Always confirm an elevated result on 2 of 3 samples before treating.
›Can you lower your uACR without medication?
Yes, in early stages. Reducing dietary sodium below 2,300 mg/day, losing 5–10% of body weight, controlling blood pressure below 130/80 mmHg, and improving glycemic control all reduce uACR. Sodium restriction amplifies the effect of ACE inhibitors and ARBs. Medication becomes standard of care once uACR persistently exceeds 30 mg/g with diabetes or hypertension present.
›Which medications lower the urine albumin/creatinine ratio most effectively?
ACE inhibitors and ARBs are first-line, reducing uACR by 30–40% in diabetic kidney disease. SGLT2 inhibitors (canagliflozin, dapagliflozin, [empagliflozin](/empagliflozin)) reduce uACR by 25–35% and have dedicated kidney outcome trial data (CREDENCE, DAPA-CKD). GLP-1 receptor agonists such as semaglutide reduced uACR by 24% in the FLOW trial. These drug classes are often combined in higher-risk patients.
›Does a uACR below 30 mg/g mean my kidneys are healthy?
Not necessarily. A uACR of 25 mg/g is clinically 'normal' by KDIGO standards but sits in the suboptimal zone under a longevity framework. It may reflect early glomerular stress from hypertension, insulin resistance, or metabolic syndrome years before overt kidney disease appears. Tracking the trend over time matters as much as any single value.
›How often should I test my uACR?
Once a year is standard for anyone with diabetes, hypertension, obesity, or a family history of kidney disease. Longevity panels typically include uACR annually starting at age 30 or earlier in high-risk individuals. If a result is above 10 mg/g, retesting every 3 months until stable is reasonable under a proactive monitoring protocol.
›Is uACR the same as a microalbumin test?
They measure the same thing but report it differently. A microalbumin test reports albumin concentration in mg/L or mcg/min (in a timed collection). The uACR divides that albumin value by urinary creatinine to correct for dilution. The ratio is more reproducible for screening purposes and is the preferred metric in KDIGO and ADA guidelines.
›What uACR level requires specialist referral to a nephrologist?
KDIGO 2024 recommends nephrology referral for uACR above 300 mg/g, eGFR below 30 mL/min/1.73 m², rapidly falling eGFR (more than 5 mL/min/year), or suspected non-diabetic kidney disease. For uACR between 30 and 300 mg/g, primary care or telehealth management with RAAS and SGLT2 inhibitor therapy is appropriate when the underlying cause is clear.
›Does SGLT2 inhibitor therapy improve uACR even without diabetes?
Yes. DAPA-CKD enrolled patients with CKD with and without type 2 diabetes, and dapagliflozin reduced the primary kidney endpoint consistently across both groups. The non-diabetic subgroup (N = 1,398) showed a hazard ratio of 0.50 (95% CI 0.35–0.72) for the composite of sustained eGFR decline, ESRD, or kidney or CV death. UACR reduction was similar regardless of diabetes status.

References

  1. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13(4):1034-1039. https://pubmed.ncbi.nlm.nih.gov/11912264/

  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. https://pubmed.ncbi.nlm.nih.gov/38490803/

  3. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423-429. https://pubmed.ncbi.nlm.nih.gov/20124537/

  4. Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet. 2008;372(9638):547-553. https://pubmed.ncbi.nlm.nih.gov/18707986/

  5. Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2010;77(1):57-64. https://pubmed.ncbi.nlm.nih.gov/19847154/

  6. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-232. https://pubmed.ncbi.nlm.nih.gov/12472787/

  7. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1

  8. Saydah SH, Pavkov ME, Zhang C, et al. Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010. Clin Chem. 2013;59(4):675-683. https://pubmed.ncbi.nlm.nih.gov/23386699/

  9. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431. https://pubmed.ncbi.nlm.nih.gov/12435255/

  10. De Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007;18(1):235-243. https://pubmed.ncbi.nlm.nih.gov/17135398/

  11. Faulx MD, Storfer-Isser A, Kirchner HL, et al. Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep. 2007;30(7):923-929. https://pubmed.ncbi.nlm.nih.gov/17682664/

  12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. https://www.nejm.org/doi/full/10.1056/NEJMoa011161

  13. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380(24):2295-2306. https://www.nejm.org/doi/full/10.1056/NEJMoa1811744

  14. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446. https://www.nejm.org/doi/full/10.1056/NEJMoa2024816

  15. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. https://www.nejm.org/doi/full/10.1056/NEJMoa2403347

  16. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. https://www.nejm.org/doi/full/10.1056/NEJMoa1511939

  17. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure. BMJ. 2011;343:d4366. https://www.bmj.com/content/343/bmj.d4366

  18. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther. 2003;10(1):3-14. https://pubmed.ncbi.nlm.nih.gov/12616464/

  19. Whelton PK, Carey RM,